drugset / Trial / NCT04261270
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
RandomizedParallel-groupSingle-blindTreatment
Summary
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2020-05-01
- Completion
- 2020-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASC09F | Unknown | 400 mg | — |
| Subject | Oseltamivir | Small molecule | 75 mg | — |
| Subject | Ritonavir | Other / unclassified | 300 mg | — |